

# Philippe Armand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/525470/publications.pdf>

Version: 2024-02-01

163  
papers

18,306  
citations

28274

55  
h-index

12946

131  
g-index

164  
all docs

164  
docs citations

164  
times ranked

17747  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.   | 27.0 | 3,099     |
| 2  | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2698-2704.   | 1.6  | 868       |
| 3  | Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.   | 1.6  | 830       |
| 4  | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.                                       | 10.7 | 818       |
| 5  | Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.  | 1.4  | 730       |
| 6  | <i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.   | 1.6  | 634       |
| 7  | Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.  | 1.6  | 586       |
| 8  | Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.   | 1.4  | 565       |
| 9  | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.          | 1.6  | 551       |
| 10 | Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.   | 27.0 | 488       |
| 11 | Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206. | 1.6  | 433       |
| 12 | Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007, 109, 4586-4588.  | 1.4  | 395       |
| 13 | Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.  | 1.6  | 359       |
| 14 | Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.   | 1.6  | 339       |
| 15 | A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.   | 1.4  | 310       |
| 16 | Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.  | 1.6  | 273       |
| 17 | Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.  | 1.6  | 265       |
| 18 | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.  | 1.4  | 259       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.   | 1.4  | 255       |
| 20 | Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.   | 1.4  | 246       |
| 21 | The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.  | 16.8 | 227       |
| 22 | PD-1 blockade for relapsed lymphoma postâ€“allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.   | 1.4  | 214       |
| 23 | Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.  | 1.4  | 209       |
| 24 | Immune checkpoint blockade in hematologic malignancies. <i>Blood</i> , 2015, 125, 3393-3400.  | 1.4  | 208       |
| 25 | Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.   | 1.6  | 195       |
| 26 | Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.   | 1.4  | 178       |
| 27 | Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.                        | 1.6  | 170       |
| 28 | PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.  | 1.4  | 156       |
| 29 | Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.       | 1.6  | 152       |
| 30 | Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.   | 1.4  | 145       |
| 31 | Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 655-664.                            | 2.0  | 135       |
| 32 | PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.  | 1.4  | 129       |
| 33 | Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.   | 5.0  | 126       |
| 34 | Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cellâ€“rich and exhausted T-effector microenvironment. <i>Blood</i> , 2018, 132, 825-836.  | 1.4  | 121       |
| 35 | Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 418-425. | 2.0  | 119       |
| 36 | A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039). <i>Blood</i> , 2016, 128, 183-183.   | 1.4  | 107       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 5767-5774.                                    | 1.6  | 105       |
| 38 | Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. <i>Blood Advances</i> , 2019, 3, 4065-4080.  | 5.2  | 99        |
| 39 | Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 852-860.   | 2.0  | 98        |
| 40 | Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.   | 1.4  | 92        |
| 41 | A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.   | 1.4  | 92        |
| 42 | Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 2643-2654.   | 5.2  | 91        |
| 43 | A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.  | 30.7 | 87        |
| 44 | Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 280-288.                 | 2.0  | 81        |
| 45 | A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. <i>Leukemia</i> , 2021, 35, 777-786.  | 7.2  | 78        |
| 46 | Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.   | 1.4  | 69        |
| 47 | Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. <i>Blood</i> , 2018, 132, 9-16.  | 1.4  | 68        |
| 48 | Prognostic factors for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. <i>British Journal of Haematology</i> , 2013, 160, 608-617.  | 2.5  | 67        |
| 49 | Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 123-126.   | 2.5  | 67        |
| 50 | The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. <i>Blood</i> , 2019, 134, 2059-2069.   | 1.4  | 66        |
| 51 | Does iron overload really matter in stem cell transplantation?. <i>American Journal of Hematology</i> , 2012, 87, 569-572.   | 4.1  | 65        |
| 52 | A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2021, 124, 744-753.  | 6.4  | 65        |
| 53 | Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1248-1251.   | 2.0  | 64        |
| 54 | Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424. | 2.0  | 62        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.   | 1.4  | 62        |
| 56 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.               | 4.6  | 60        |
| 57 | Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018, 6, 630-635.                           | 3.4  | 59        |
| 58 | A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 28-35.   | 2.0  | 57        |
| 59 | Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.  | 2.0  | 56        |
| 60 | Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.  | 3.5  | 54        |
| 61 | The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104. | 2.5  | 53        |
| 62 | Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. <i>European Journal of Cancer</i> , 2020, 136, 4-6.   | 2.8  | 53        |
| 63 | Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 1391-1402.  | 10.7 | 53        |
| 64 | A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.  | 2.5  | 51        |
| 65 | Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> , 2020, 5, .   | 5.0  | 51        |
| 66 | Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.   | 2.5  | 47        |
| 67 | Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.  | 2.0  | 45        |
| 68 | Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.   | 7.2  | 45        |
| 69 | Allogeneic Stem Cell Transplantation for Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 505-516.   | 2.0  | 44        |
| 70 | Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.   | 5.2  | 44        |
| 71 | Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.    | 3.5  | 43        |
| 72 | Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.                          | 4.1  | 42        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.  | 5.2 | 40        |
| 74 | Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611. | 2.0 | 39        |
| 75 | Early <sup>18</sup> F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 649-654.   | 5.0 | 39        |
| 76 | KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. <i>Blood Advances</i> , 2020, 4, 2617-2622.   | 5.2 | 38        |
| 77 | Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. <i>Journal of Clinical Oncology</i> , 2017, 35, 3877-3887.  | 1.6 | 36        |
| 78 | Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.   | 2.0 | 36        |
| 79 | Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.   | 2.0 | 33        |
| 80 | Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.   | 3.5 | 31        |
| 81 | Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1353-1364.   | 1.4 | 31        |
| 82 | Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.           | 2.0 | 29        |
| 83 | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 478-486.   | 7.0 | 29        |
| 84 | Pembrolizumab in relapsed or refractory Richter syndrome. <i>British Journal of Haematology</i> , 2020, 190, e117-e120.  | 2.5 | 29        |
| 85 | Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.   | 3.7 | 28        |
| 86 | Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.   | 5.2 | 28        |
| 87 | Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.  | 1.4 | 28        |
| 88 | A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.  | 3.5 | 27        |
| 89 | Minimal residual disease in non-Hodgkin lymphoma â€“ current applications and future directions. <i>British Journal of Haematology</i> , 2018, 180, 177-188.   | 2.5 | 25        |
| 90 | A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.  | 7.2 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.   | 3.5 | 24        |
| 92  | Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.   | 1.4 | 24        |
| 93  | Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.   | 5.2 | 23        |
| 94  | Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.   | 5.2 | 22        |
| 95  | Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3502-3502.  | 1.4 | 21        |
| 96  | Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.   | 2.5 | 19        |
| 97  | An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2084-2091.             | 2.0 | 16        |
| 98  | Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 17-22.   | 2.0 | 16        |
| 99  | Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm. <i>Journal of Clinical Oncology</i> , 2020, 38, 3565-3574.   | 1.6 | 16        |
| 100 | BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.  | 5.2 | 16        |
| 101 | The Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1785.  | 3.7 | 16        |
| 102 | Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.                                 | 1.4 | 16        |
| 103 | Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.  | 3.5 | 15        |
| 104 | Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.   | 2.4 | 15        |
| 105 | A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2021, 138, 132-132.   | 1.4 | 15        |
| 106 | Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 575-585.   | 2.2 | 14        |
| 107 | Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539. | 2.0 | 14        |
| 108 | A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, . .  | 7.2 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.  | 0.7 | 13        |
| 110 | Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954. | 1.3 | 13        |
| 111 | Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 44-50.   | 2.3 | 12        |
| 112 | Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.  | 2.5 | 11        |
| 113 | Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.                                   | 2.0 | 9         |
| 114 | Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1465-1475.   | 3.4 | 8         |
| 115 | Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 115-125.  | 1.5 | 7         |
| 116 | Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.                            | 1.2 | 7         |
| 117 | HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana. <i>JCO Global Oncology</i> , 2022, 8, e2100163.   | 1.8 | 7         |
| 118 | Refractory myeloid sarcoma with a FIP1L1-PDGFR $\alpha$ rearrangement detected by clinical high throughput somatic sequencing. <i>Experimental Hematology and Oncology</i> , 2015, 4, 30.   | 5.0 | 6         |
| 119 | Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1063-1074.   | 1.3 | 6         |
| 120 | Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.                      | 1.4 | 5         |
| 121 | Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence. <i>Blood</i> , 2018, 132, 678-678.   | 1.4 | 5         |
| 122 | Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.      | 1.4 | 5         |
| 123 | Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.  | 1.4 | 5         |
| 124 | Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 3069-3069.  | 1.4 | 5         |
| 125 | Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2021, 138, 306-306.  | 1.4 | 5         |
| 126 | Hyperferritinemia in Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 336-337.   | 2.0 | 4         |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Pulp Obliteration in a Patient with Sclerodermatous Chronic Graft-versus-Host Disease. <i>Journal of Endodontics</i> , 2016, 42, 678-680.   | 3.1  | 4         |
| 128 | The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 11-21.   | 2.3  | 4         |
| 129 | Immune and Cell Therapy in Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 269-277.  | 2.0  | 4         |
| 130 | Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2020, 136, 45-46.            | 1.4  | 4         |
| 131 | Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1947-1947.  | 1.4  | 4         |
| 132 | Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640. | 1.4  | 4         |
| 133 | Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.                                | 1.4  | 4         |
| 134 | PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.  | 1.4  | 3         |
| 135 | R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.  | 1.4  | 3         |
| 136 | Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1635-1635.   | 1.4  | 3         |
| 137 | Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013, 122, 695-695.  | 1.4  | 3         |
| 138 | The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. <i>Blood</i> , 2013, 122, 704-704.                                  | 1.4  | 3         |
| 139 | Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion. <i>Blood</i> , 2018, 132, 1559-1559.   | 1.4  | 2         |
| 140 | Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 595-595.  | 1.4  | 2         |
| 141 | Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.        | 1.4  | 2         |
| 142 | Case 37-2020: A 35-Year-Old Man with Lymphadenopathy and Petechiae. <i>New England Journal of Medicine</i> , 2020, 383, 2159-2169.  | 27.0 | 1         |
| 143 | Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. <i>Blood</i> , 2019, 134, 3275-3275.                                    | 1.4  | 1         |
| 144 | Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.  | 1.4  | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. Blood, 2007, 110, 2016-2016.  | 1.4 | 1         |
| 146 | Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 2122-2122. | 1.4 | 1         |
| 147 | Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2014, 124, 2496-2496.  | 1.4 | 1         |
| 148 | Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.   | 1.4 | 1         |
| 149 | Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.  | 1.6 | 0         |
| 150 | Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, S9-S14.  | 2.0 | 0         |
| 151 | Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma. European Journal of Cancer, 2020, 131, 51-52.  | 2.8 | 0         |
| 152 | A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leukemia and Lymphoma, 2021, 62, 478-481.  | 1.3 | 0         |
| 153 | Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.   | 1.4 | 0         |
| 154 | Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.   | 1.4 | 0         |
| 155 | A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 327-327.  | 1.4 | 0         |
| 156 | Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.  | 1.4 | 0         |
| 157 | Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4136-4136.  | 1.4 | 0         |
| 158 | Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.  | 1.4 | 0         |
| 159 | Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. Blood, 2014, 124, 3961-3961.   | 1.4 | 0         |
| 160 | BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3425-3425.  | 1.4 | 0         |
| 161 | Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. Blood, 2019, 134, 1493-1493.   | 1.4 | 0         |
| 162 | Hodgkin Lymphoma and PD-1 Blockade. Hematologic Malignancies, 2020, , 395-409.   | 0.2 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy. Blood, 2021, 138, 3924-3924. | 1.4 | 0         |